Comparative effectiveness of intra-articular administration of different drugs of hyaluronic acid with various physico-chemical properties in knee osteoarthritis

Knee osteoarthritis (KOA) is a chronic disease that leads to a significant deterioration in the quality of life and disability. In the treatment of OA, hyaluronic acid (HA) drugs have an important place.

Objective: to compare the effectiveness of ROA treatment with different HA drugs with different physicochemical properties and molecular weight.

Patients and methods. A 12-week prospective randomized study of the comparative efficacy of a single intra-articular injection of three HA drugs – Armaviscon Forte (AF), Flexotron Cross (FCr) and Flexotron Ultra (FUL) was carried out. The study group consisted of 90 patients with knee osteoarthritis, aged from 43 to 50 years (the majority were women – 63.3%) with an initial severity of pain >40 mm according to the visual analogue scale (VAS). The result of therapy was assessed by the dynamics of pain (VAS), WOMAC index, and subjective assessment of the effect 3 months after intra-articular administration of HA.

Results and discussion. Eight patients dropped out of the study: in the AF group – 3, FCr – 4, FUL – 1. After 90 days, the decrease in pain compared to baseline values in the AF group was 30%, in FCr – 46% and in FUL – 57% (p ≤0,05), and the dynamics of the WOMAC index – 27, 36, and 42%, respectively. After 90 days, 85.0, 93.4 and 96.5% of patients noted improvement and significant improvement in the AF, FCr and FUL groups, respectively. No serious adverse events were recorded.

Conclusion. All investigated drugs demonstrated high analgesic potential, but the best clinical effect was observed with FUL.

1. Nasonov EL, redaktor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 240 p.

2. Nasonova VA. The problem of osteoarthritis at the beginning of the XXI century. Consilium Medicum. 2000;(2): 61-4. (In Russ.).

3. Balabanova RM. Osteoarthrosis or osteoarthritis? A current view of the disease and its treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013; 7 (3):67-70. (In Russ.). doi: 10.14412/1996-7012-2013-276

4. Alekseeva LI. Update of clinical recommendations for the treatment of osteoarthritis patients in 2019. Russkii meditsinskii zhurnal. 2019;(4):2-6. (In Russ.).

5. Balabanova RM. Place of hyaluronic acid preparations in therapy for osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;8(3):73-6. (In Russ.). doi: 10.14412/1996-7012-2014- 3-73-76

6. Henrotin Y, Raman R, Richette P, et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheum. 2015 Oct;45(2):140-9. doi: 10.1016/j.semarthrit. 2015.04.011. Epub 2015 Apr 30

7. Khitrov NA. Modern possibilities of synovial fluid implants in osteoarthritis. Russkii meditsinskii zhurnal. 2014;(7):499-503. (In Russ.)].

8. Strebkova EA, Alekseeva LI. Efficiency of intra-articular hyaluronic acid therapy in patients with osteoarthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):96-104. (In Russ.). doi: 10.14412/1996-7012-2019-2-96-104

9. Anikin SG, Alekseeva LI. The use of hyaluronic acid preparations for osteoarthritis of the knee joints. Nauchno-prakticheskaya revmatologiya. 2013;51(4):439-45. (In Russ.).

10. Khabarov VN, Boikov PYa, Selyanin MA. Gialuronovaya kislota [Hyaluronic Acid]. Moscow; 2012.

11. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005321. doi: 10. 1002/14651858.CD005321.pub2.

12. Altman RD. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015 Oct 26;16:321. doi: 10.1186/s12891-015-0775-z.

13. Koga H. Effects of hyaluronic acid on arthritic articular cartilage. Connect Tissue Res. 2012;53(1):48-93. doi: 10.3109/03008207. 2011.637147

14. Toole BP. Hyaluronan in morphogenesis. Semin Cell Dev Biol. 2001 Apr;12(2):79-87. doi: 10.1006/scdb.2000.0244.

15. Stern R. Devising a pathway for hyaluronan catabolism. Are we there yet? Glycobiology. 2003 Dec;13(12):105R-115R. doi: 10.1093/glycob/cwg112. Epub 2003 Sep 26.

16. Bollyky PL, Falk BA, Wu RP, et al. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells. J Leukoc Biol. 2009 Sep;86(3):567-72. doi: 10.1189/jlb.0109001. Epub 2009 Apr 28.

17. Goueffic Y, Guilluy C, Guerin P, et al. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res. 2006 Nov 1;72(2):339-48. doi: 10.1016/j.cardiores.2006.07.017. Epub 2006 Jul 29.

18. Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal antiinflammatory drugs. Klinicheskie rekomendatsii. Nauchno-prakticheskaya revmatologiya. 2018;56(Suppl.1):1-29. (In Russ.).

19. Maheu E, Zaїm M, Appelboom T, et al. Evaluation of intra articular injections of hyaluronic acid and chondroitine sulfate for knee arthritis treatment: a multicentric pilot study with 3 months follow-up. National rheumatolgy meeting; 2010 (Societe Franeaise de Rheumatologie).

20. Taskina EA, Kashevarova NG, Sharapova EP, et al. Evaluation of the efficacy and safety of hyaluronic acid in patients with osteoarthritis of the knee joints (preliminary data). Nauchno-prakticheskaya revmatologiya. 2018;56 (Suppl. 2):77. (In Russ.).

21. Petrella RJ, Wakeford C. Pain relief and improved physical function in knee osteoarthritis patients receiving ongoing hylan G-F 20, a high-molecular-weight hyaluronan, versus other treatment options: data from a large real-world longitudinal cohort in Canada. Drug Des Devel Ther. 2015 Oct 15; 9: 5633-40. doi: 10.2147/DDDT.S88473

22. Miller LE, Block JE. US-approved intraarticular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and metaanalysis of randomized, saline-controlled trials. Clin Med Insights Arthritis Musculoskelet Disord. 2013 Sep 1;6:57-63. doi: 10.4137/ CMAMD.S12743. eCollection 2013.

23. Filatova YuS, Gauert VR. Hyaluronic acid with intra-articular administration: dependence of the effect on molecular weight. Russkii meditsinskii zhurnal. 2021;(3):156-61. (In Russ.).

24. Anikin SG, Kashevarova NG, Korotkova TA, et al. Evaluation of the efficacy, tolerability and safety of intra-articular administration of hyaluronic acid in patients with osteoarthritis of the knee joints. Lechashchii vrach.2014; (12):92-5. (In Russ.).

25. Popov VP, Koroshchenko SA, Larin MA. Optimal use of hyaluronic acid preparations in joint pathology. Russkii meditsinskii zhurnal. 2017;(1):12-4. (In Russ.).

26. Olyunin YuA. Use of hyaluronic acid preparations in the combination therapy of osteoarthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(2): 64-9. (In Russ.). doi: 10.14412/1996-7012- 2016-2-64-69

27. Altman RD. Status ot hyaluronan supplementation therapy in osteoarthritis. Curr Rheumatol Rep. 2003 Feb;5(1):7-14. doi: 10.1007/s11926-003-0077-6.

28. Fedorishchev IA. Gialuronovaya kislota: monografiya. Kniga 1 [Hyaluronic acid: monograph. Book 1]. Tula: TulGU; 2011. 237 p.

29. Bannuru RR, Schmid CH, Kent DM, et al. Сomparative effectiveness of pharmacologic interventions of knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015 Jan 6;162(1):46-54. doi: 10.7326/M14-1231.